NCT01822652Fut, nem toboroz1. fázis
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. ápr. 6.
Rövid összefoglaló (regiszter, angolul)
Subjects that have relapsed or refractory neuroblastoma are invited to take part in this gene transfer research study. We have found from previous research that we can put a new gene called a chimeric antigen receptor (CAR) into T cells that will make them recognize neuroblastoma cells and kill them. In a previous clinical trial, we used a CAR that recognizes GD2, a protein found on almost all neuroblastoma cells (GD2-CAR). We put this gene into T cells and gave them back to patients that had neuroblastoma. The infusions were safe and in patients with disease at the time of their infusion, the time to progression was longer if we could find GD2 T cells in their blood for more than 6 weeks. Because of this, we think that if T cells are able to last longer, they may have a better chance of killing neuroblastoma tumor cells. Therefore, in this study we will add new genes to the GD2 T cells that can cause the cells to live longer. These new genes are called CD28 and OX40. The purpose of this study will be to determine the highest dose of iC9-GD2-CD28-OX40 (iC9-GD2) T cells that can safely be given to patients with relapsed/refractory neuroblastoma. In other clinical studies using T cells, some investigators found that giving chemotherapy before the T cell infusion can improve the amount of time the T cells stay in the body and therefore the effect the T cells can have. This is called lymphodepletion and we think that it will allow the T cells we infuse to expand and stay longer in the body, and potentially kill cancer cells more effectively. The chemotherapy we will use for lymphodepletion is a combination of cyclophosphamide and fludarabine. Additionally, to effectively kill the tumor cells, it is important that the T cells are able to survive and expand in the tumor. Recent studies have shown that solid tumors release a substance (PD1) that can inhibit T cells after they arrive into the tumor tissue. In an attempt to overcome the effect of PD1 in neuroblastoma we will also give a medication called pembrolizumab.
- Állapot (regiszter)
- Fut, nem toboroz
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 11 (tényleges)
- Első benyújtás
- 2013. márc. 28.
- Kezdés
- 2013. aug.
- Elsődleges befejezés
- 2015. dec.
- Fő szponzor
- Baylor College of Medicine
- Betegségek
- Neuroblasztóma, Gyermekkori daganatok
- NCT-szám
- NCT01822652
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1. fázis
- Bevont résztvevők: 11
- 2013. aug. és az elsődleges befejezés (2015. dec.) között
- 2 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Currently receiving other investigational drugs
- Patients currently receiving immunosuppressive drugs such as corticosteroids, tacrolimus or cyclosporine
- Patients previously experienced severe toxicity from cyclophosphamide or fludarabine
- Severe previous toxicity from pembrolizumab or other PD-1 targeted antibody
Más betegség
- Rapidly progressive disease
- History of hypersensitivity to murine protein containing products
- TREATMENT:
- Rapidly progressive disease
- History of hypersensitivity to murine protein containing products
- History of cardiomegaly or bilateral pulmonary infiltrates on chest radiograph or CT. However, patients with cardiomegaly on imaging may be enrolled if they have an assessment of cardiac function (i.e., ECHO or MUGA) within 3 weeks of starting protocol therapy that is within normal limits. Additionally, patients with bilateral pulmonary infiltrates on imaging may be enrolled if the lesions are not consistent with active neuroblastoma (i.e., negative on functional imaging with PET or MIBG, or by pathologic assessment).
Egyéb
- PROCUREMENT:
- Evidence of tumor potentially causing airway obstruction
- Patients who are pregnant, lactating, or unwilling to use birth control
Kiket keres a vizsgálat
- PROCUREMENT
- High risk neuroblastoma with persistent or relapsed disease
- Life expectancy of at least 12 weeks
- Karnofsky/Lansky score of 60% or greater
- Absence of HAMA prior to enrollment (only in patients that have been previously treated with murine antibodies)
- Informed consent and assent (as applicable) obtained from parent/guardian and child
- TREATMENT:
- High risk neuroblastoma with persistent or relapsed disease
- Life expectancy of at least 12 weeks
- Karnofsky/Lansky score of 60% or greater
- Patients must have an ANC greater than or equal to 500, platelet count greater than or equal to 20,000
- Pulse Ox greater than or equal to 90% on room air
- AST and ALT less than 5 times the upper limit of normal
- Total bilirubin less than 3 times the upper limit of normal
- Serum creatinine less than 3 times upper limit of normal. Creatinine clearance is needed for patients with creatinine greater than 1.5 times upper limit of normal
- TSH normal for age. Patients using thyroid medication to facilitate a euthyroid state must be on a stable dose for at least 1 month prior to planned infusion
- Recovered from acute effects of all prior chemotherapy. If some effects of therapy have become chronic (i.e., treatment associated thrombocytopenia), the patient must be clinically stable and meet all other eligibility criteria
- Absence of human anti-mouse antibodies (HAMA) prior to enrollment for patients who have received prior therapy with murine antibodies
- Patients must have autologous transduced activated T-cells with greater than or equal to 20% expression of GD2
- Pembrolizumab available for infusion
- Informed consent and assent (as applicable) obtained from parent/guardian and child
Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (2)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Houston Methodist Hospital Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát | Houston | Egyesült Államok | Ismeretlen állapot |
| Texas Children's Hospital Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát | Houston | Egyesült Államok | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.